Non-invasive Evaluation of the Predictive Value of CEUS and SWE in Patients With and Without TIPS With ACLF, Renal Failure and Hepatorenal Syndrome

What this Trial Is About

This research aims to evaluate non-invasive methods to predict outcomes in patients who develop acute-on-chronic liver failure (ACLF) and kidney failure, focusing on those who receive or do not receive a transjugular intrahepatic portosystemic shunt (TIPS). The study involves patients diagnosed with cirrhosis based on clinical, hemodynamic, biochemical, ultrasound, or biopsy criteria and follows a standardized routine care program. Participants are divided into two groups: those who receive TIPS and those who do not. Both groups undergo structured routine evaluations and follow-up as part of their standard care. Clinical and laboratory data collected during these visits are analyzed to assess their potential prognostic value for liver and kidney complications. Throughout the study, participants are monitored for survival up to 10 years, along with other important health events such as ascites, hepatic encephalopathy, variceal bleeding, liver failure, acute-on-chronic liver failure, kidney failure, and other organ failures. The researchers review data from regular clinical care visits without altering treatment, allowing long-term observation of patient outcomes under usual care conditions.

Non-invasive Evaluation of the Predictive Value of CEUS and SWE in ACLF, Renal Failure and Hepatorenal Syndrome